; (B) reduce by 90 percent the tuberculosis incidence rate by 2035; and (C) reduce by 100 percent the number of families facing catastrophic health costs due to tuberculosis by 2035; (2) support the Stop TB Partnership’s Global Plan to End TB 2016–2020, including support for— (A) development and use of innovative new technologies and therapies to increase active case finding to rapidly diagnose and treat children and adults with all forms of tuberculosis, alleviate suffering, and ensure tuberculosis treatment completion; (B) the diagnosis and treatment of latent tuberculosis infection, in support of the global goal of providing preventive therapy to at least 30,000,000 people, including 4,000,000 children under five years of age, 20,000,000 household contacts of people affected by tuberculosis, and 6,000,000 people living with HIV, by 2022; (C) steps to ensure high-quality tuberculosis care by closing gaps in care cascades, implementing continuous quality improvement at all levels of care, and providing patient support; and (D) sustainable procurement of tuberculosis commodities, to avoid interruptions in supply, procurement of commodities of unknown quality, or payment of excessive commodity costs in countries impacted by tuberculosis; (3) ensure United States funding supports activities that simultaneously emphasize— (A) the development of comprehensive person-centered programs which include diagnosis, treatment, and prevention strategies to ensure that those at high risk for infection are found and treated with preventive therapies in a timely manner; (B) robust tuberculosis infection control practices in all congregate settings, including hospitals and prisons; (C) the deployment of diagnostic and treatment capacity in areas with the highest tuberculosis burdens, as well as for highly at-risk and impoverished populations, including patient support